Selected cell delivery for heart failure
View Patent ↗This invention provides methods of increasing blood flow to tissue in a subject in need thereof, methods of regenerating tissue in a subject, methods of treating diseased tissue in a subject, methods of forming new blood vessels in tissue and new tissue, such as myocardial tissue, in a subject in need thereof, methods of increasing angiogenesis in diseased tissue in a subject, and methods of preventing heart failure in a subject, which methods comprise: a) isolating autologous mononuclear cells from the subject; b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin − ) mononuclear cells; and c) transplanting locally into or adjacent to the tissue an effective amount of the Lin − autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue. Additional methods provided for such uses further select from the isolated autologous mononuclear cells of step (a) lineage negative (Lin − ) mononuclear cells a subset of Lin − mononuclear side population (SP) cells and transplant locally into or adjacent to the tissue an effective amount of the Lin − SP cells. In other aspects, methods using tissue other than mononuclear cells for these uses are provided, which comprise (a) obtaining a cell suspension from the tissue or a second tissue of the subject; (b) selecting from the cell suspension step (a) side population (SP) cells; and (c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue.
1. A method of increasing blood flow to tissue in a subject in need thereof which comprises:
a) isolating autologous mononuclear cells from cardiac muscle from the subject;
b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin − ) mononuclear cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the Lin − autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby increasing blood flow to the tissue.
2. The method of claim 1 , further comprising:
(i) selecting from the Lin − mononuclear cells of step (b) side population (SP) cells; and
(ii) transplanting locally into or adjacent to the tissue an effective amount of the Lin − SP cells.
3. The method of claim 1 , wherein the tissue is ischemic tissue.
4. The method of claim 3 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.
5. A method of increasing blood flow to tissue in a subject in need thereof which comprises:
a) obtaining a cell suspension from cardiac muscle of the subject;
b) selecting from the cell suspension of step (a) side population (SP) cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby increasing blood flow to the tissue.
6. The method of claim 5 , wherein the SP cells are selected by staining with a nuclear dye, wherein the SP cells exclude staining from nuclei.
7. The method of claim 5 , wherein the tissue is ischemic tissue.
8. The method of claim 7 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.
9. A method of regenerating tissue in a subject which comprises:
a) isolating autologous mononuclear cells from cardiac muscle from the subject;
b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin − ) mononuclear cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the Lin − autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby regenerating the tissue.
10. The method of claim 9 , further comprising:
(i) selecting from the Lin − mononuclear cells of step (b) side population (SP) cells; and
(ii) transplanting locally into or adjacent to the tissue an effective amount of the Lin − SP cells.
11. The method of claim 9 , wherein the tissue is ischemic tissue.
12. The method of claim 11 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.
13. A method of regenerating tissue in a subject which comprises:
a) obtaining a cell suspension from cardiac muscle of the subject;
b) selecting from the cell suspension of step (a) side population (SP) cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby regenerating the tissue.
14. The method of claim 13 , wherein the SP cells are selected by staining with a nuclear dye, wherein the SP cells exclude staining from nuclei.
15. The method of claim 13 , wherein the tissue is ischemic tissue.
16. The method of claim 15 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.
17. A method of treating diseased tissue in a subject which comprises:
a) isolating autologous mononuclear cells from cardiac muscle from the subject;
b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin − ) mononuclear cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the Lin − autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby treating the diseased tissue.
18. The method of claim 17 , further comprising:
i) selecting from the Lin − mononuclear cells of step (b) side population (SP) cells; and
ii) transplanting locally into or adjacent to the tissue an effective amount of the Lin − SP cells.
19. The method of claim 17 , wherein the tissue is ischemic tissue.
20. The method of claim 19 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.
21. A method of treating diseased tissue in a subject which comprises:
a) obtaining a cell suspension from cardiac muscle of the subject;
b) selecting from the cell suspension of step (a) side population (SP) cells; and
c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue, thereby treating the diseased tissue.
22. The method of claim 21 , wherein the SP cells are selected by staining with a nuclear dye, wherein the SP cells exclude staining from nuclei.
23. The method of claim 21 , wherein the tissue is ischemic tissue.
24. The method of claim 23 , wherein the ischemic tissue is cardiac muscle tissue or skeletal muscle tissue.